

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/684794/publications.pdf>

Version: 2024-02-01

189
papers

20,353
citations

18465

62
h-index

11047

137
g-index

197
all docs

197
docs citations

197
times ranked

26516
citing authors

#	ARTICLE	IF	CITATIONS
1	TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8 ⁺ T cell and XCR1 ⁺ dendritic cell spatial co-localization. , 2022, 10, e003571.		13
2	TGF- β -mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity, 2022, 55, 115-128.e9.	6.6	62
3	Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Medicine, 2022, 14, 35.	3.6	29
4	Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. Cancer Discovery, 2022, 12, 1294-1313.	7.7	18
5	IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. Cancer Research, 2022, 82, 859-871.	0.4	21
6	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T β cells. Cancer Cell, 2022, 40, 545-557.e13.	7.7	53
7	Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality. Cancer Research, 2022, 82, 2156-2170.	0.4	23
8	Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures. Cancer Research, 2022, 82, 1724-1735.	0.4	6
9	Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1006-1016.	1.1	6
10	Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma. PLoS ONE, 2022, 17, e0264014.	1.1	1
11	Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents. International Journal of Molecular Sciences, 2022, 23, 5129.	1.8	4
12	Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors. Molecular Cancer Therapeutics, 2022, 21, 1184-1194.	1.9	12
13	T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. , 2022, 10, e004512.		14
14	β T cells share the spotlight in cancer. Nature Cancer, 2022, 3, 657-658.	5.7	4
15	Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors. Immunological Investigations, 2022, 51, 2215-2225.	1.0	5
16	Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 425-435.	0.4	35
17	IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature, 2021, 591, 464-470.	13.7	99
18	The prognostic and predictive implications of the 12-chemokine score in muscle invasive bladder cancer.. Journal of Clinical Oncology, 2021, 39, 466-466.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	6
20	Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 710-718.	1.1	9
21	CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from $\hat{\pm}$ PD-L1 and include tissue-selective $\hat{\beta}$ T cell activation. , 2021, 9, e002051.		12
22	Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. <i>Molecular Therapy</i> , 2021, 29, 1541-1556.	3.7	20
23	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2621-2633.	0.6	137
24	The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. <i>Frontiers in Immunology</i> , 2021, 12, 694079.	2.2	10
25	Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. <i>Nature Reviews Urology</i> , 2021, 18, 543-555.	1.9	20
26	The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. <i>Frontiers in Immunology</i> , 2021, 12, 735609.	2.2	10
27	Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1410-1418.	15.2	168
28	Clinical characteristics and prognostic factors of 70 patients with SÃ©zary syndrome: a single-institutional experience at Moffitt cancer center. <i>Leukemia and Lymphoma</i> , 2021, , 1-8.	0.6	1
29	B cells and cancer. <i>Cancer Cell</i> , 2021, 39, 1293-1296.	7.7	52
30	Cover Image, Volume 60, Issue 2. <i>Molecular Carcinogenesis</i> , 2021, 60, i.	1.3	0
31	Wide and deep learning for automatic cell type identification. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1052-1062.	1.9	8
32	Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2021, 60, 138-150.	1.3	11
33	PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 428-435.	0.9	14
34	Humoral immune responses: Unsung heroes of the war on cancer. <i>Seminars in Immunology</i> , 2020, 49, 101419.	2.7	11
35	Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. <i>Cell Metabolism</i> , 2020, 32, 420-436.e12.	7.2	72
36	CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. <i>Cancer Research</i> , 2020, 80, 5063-5075.	0.4	21

#	ARTICLE	IF	CITATIONS
37	COX-Prostaglandin Pathway Inhibition May Augment the Effects of Immunotherapy in Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 231, S34-S35.	0.2	0
38	BTN3A1 governs antitumor responses by coordinating $\hat{I}\hat{\pm}\hat{I}^2$ and $\hat{I}\hat{3}\hat{I}$ T cells. <i>Science</i> , 2020, 369, 942-949.	6.0	83
39	Loss of <i>microRNA-21</i> leads to profound stromal remodeling and short survival in <i>Ras</i> -driven mouse models of pancreatic cancer. <i>International Journal of Cancer</i> , 2020, 147, 2265-2278.	2.3	14
40	Kindlin-3 gives patrolling monocytes a strong grip. <i>Journal of Leukocyte Biology</i> , 2020, 107, 879-881.	1.5	0
41	Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. , 2020, 8, e000796.		7
42	The Association of <i>MUC16</i> Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1792-1799.	1.1	15
43	Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 1474-1485.	3.2	62
44	The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. <i>Immunity</i> , 2020, 52, 668-682.e7.	6.6	107
45	68...The prognostic and predictive implications of the 12-chemokine score in muscle invasive bladder cancer. , 2020, , .		1
46	Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial. <i>Cancer Research</i> , 2020, 80, CT056-CT056.	0.4	14
47	c-Maf: a bad influence in the education of macrophages. <i>Journal of Clinical Investigation</i> , 2020, 130, 1629-1631.	3.9	11
48	Abstract 5719: Tumor-suppressive stromal activity of pro-fibrogenic microRNA-21 in initiation and progression of K-Ras-driven mouse models of pancreatic cancer. , 2020, , .		0
49	93...Targeting sirt2 rescues the metabolic fitness and effector functions of tumor-reactive T cells within the metabolically restricted tumor microenvironment. , 2020, , .		0
50	280...Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients. , 2020, , .		0
51	AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019, 79, 5034-5047.	0.4	37
52	Estimation of immune cell content in tumor using single-cell RNA-seq reference data. <i>BMC Cancer</i> , 2019, 19, 715.	1.1	32
53	Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer. <i>Journal of Immunology</i> , 2019, 203, 3447-3460.	0.4	126
54	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. <i>Cancer Cell</i> , 2019, 35, 885-900.e10.	7.7	475

#	ARTICLE	IF	CITATIONS
55	Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies. <i>Frontiers in Physics</i> , 2019, 7, .	1.0	3
56	ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. <i>Nature Communications</i> , 2019, 10, 1280.	5.8	83
57	Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse. <i>PLoS ONE</i> , 2019, 14, e0212930.	1.1	12
58	Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-16.	1.0	16
59	IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment. <i>OncImmunology</i> , 2019, 8, e1515058.	2.1	14
60	Breaking barriers for T cells by targeting the EPHA2/TGF- β 2/COX-2 axis in pancreatic cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 3521-3523.	3.9	13
61	Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5596-TPS5596.	0.8	2
62	CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. <i>Nature Communications</i> , 2018, 9, 631.	5.8	72
63	Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. <i>Journal of Leukocyte Biology</i> , 2018, 103, 799-805.	1.5	72
64	Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. <i>Cell Reports</i> , 2018, 22, 3393-3400.	2.9	77
65	Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 2887.	2.2	19
66	IRE1 α -XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. <i>Nature</i> , 2018, 562, 423-428.	13.7	252
67	Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer. <i>Cell</i> , 2018, 175, 679-694.e22.	13.5	344
68	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018, 24, 5347-5356.	3.2	253
69	PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. <i>Integrative Cancer Science and Therapeutics</i> , 2018, 5, .	0.1	38
70	Abstract SY01-02: Blockade of estrogen signaling boosts antitumor immunity by dwindling cancer-promoting myelopoiesis. , 2018, , .		0
71	Targeted Therapy and Immunosuppression in the Tumor Microenvironment. <i>Trends in Cancer</i> , 2017, 3, 19-27.	3.8	57
72	SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. <i>Immunity</i> , 2017, 46, 51-64.	6.6	122

#	ARTICLE	IF	CITATIONS
73	Immunotherapy for Breast Cancer: Current and Future Strategies. <i>Current Surgery Reports</i> , 2017, 5, 1.	0.4	31
74	Characterization of Novel Immune Checkpoint Receptors within the Breast Cancer Tumor Microenvironment. <i>Journal of the American College of Surgeons</i> , 2017, 225, S21.	0.2	0
75	ARID1A-mutated ovarian cancers depend on HDAC6 Activity. <i>Nature Cell Biology</i> , 2017, 19, 962-973.	4.6	173
76	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 1152-1161.	1.6	309
77	Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. <i>Cancer Discovery</i> , 2017, 7, 72-85.	7.7	153
78	Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. <i>Clinical Cancer Research</i> , 2017, 23, 441-453.	3.2	77
79	Estrogens drive myeloid-derived suppressor cell accumulation. <i>Oncoscience</i> , 2017, 4, 5-6.	0.9	5
80	Abstract 3707: Tumor-associated neutrophils with antigen-presenting features in early-stage human lung cancer. , 2017, , .		0
81	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. <i>Cancer Cell</i> , 2016, 30, 120-135.	7.7	311
82	Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, .	7.1	83
83	Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways. <i>Journal of Molecular Biology</i> , 2016, 428, 3266-3281.	2.0	67
84	State-of-the-art of regulatory dendritic cells in cancer. , 2016, 164, 97-104.		43
85	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. <i>Cancer Research</i> , 2016, 76, 6964-6974.	0.4	294
86	The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3348-3360.	2.5	23
87	BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. <i>Cell Reports</i> , 2016, 16, 2829-2837.	2.9	331
88	Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. <i>Oncogenesis</i> , 2016, 5, e267-e267.	2.1	28
89	BET Inhibitors Suppress ALDH Activity by Targeting <i>ALDH1A1</i> Super-Enhancer in Ovarian Cancer. <i>Cancer Research</i> , 2016, 76, 6320-6330.	0.4	115
90	Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. <i>Cancer Research</i> , 2016, 76, 6253-6265.	0.4	46

#	ARTICLE	IF	CITATIONS
91	Galectin-1 is essential for the induction of MOG ₃₅₋₅₅ -based intravenous tolerance in experimental autoimmune encephalomyelitis. <i>European Journal of Immunology</i> , 2016, 46, 1783-1796.	1.6	24
92	IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. <i>Cancer Research</i> , 2016, 76, 2561-2572.	0.4	26
93	Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells. <i>Cell Reports</i> , 2016, 14, 1774-1786.	2.9	89
94	Local Hyperthermia Treatment of Tumors Induces CD8+ T Cell-Mediated Resistance Against Distal and Secondary Tumors. <i>Frontiers in Nanobiomedical Research</i> , 2016, , 309-347.	0.1	3
95	Abstract IA32: Commensal microorganisms and polymorphic mucosal surfaces determine the evolution of distal metastatic tumors. , 2016, , .		0
96	Abstract A02: The origin and role of APC-like hybrid tumor-associated neutrophils in early-stage human lung cancer. , 2016, , .		0
97	Myristoylated p110 α Causes Embryonic Death Due to Developmental and Vascular Defects. <i>Open Life Sciences</i> , 2015, 10, 461-478.	0.6	5
98	ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. <i>Cell</i> , 2015, 161, 1527-1538.	13.5	639
99	The Tumor Microenvironment. <i>Advances in Cancer Research</i> , 2015, 128, 235-262.	1.9	48
100	Small but Mighty: Selected Commensal Bacterial Species Determine the Effectiveness of Anti-cancer Immunotherapies. <i>Immunity</i> , 2015, 43, 1037-1039.	6.6	2
101	Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. <i>Nature Medicine</i> , 2015, 21, 231-238.	15.2	530
102	Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model. <i>Vaccine</i> , 2015, 33, 4313-4320.	1.7	33
103	TLR5 signaling, commensal microbiota and systemic tumor promoting inflammation: the three parcae of malignant progression. <i>Oncolmmunology</i> , 2015, 4, e1021542.	2.1	7
104	Telomeric repeat-containing RNA (TERRA) constitutes a nucleoprotein component of extracellular inflammatory exosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6293-300.	3.3	76
105	Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation. <i>Cancer Cell</i> , 2015, 27, 27-40.	7.7	242
106	Size does not matter: commensal microorganisms forge tumor-promoting inflammation and anti-tumor immunity. <i>Oncoscience</i> , 2015, 2, 239-246.	0.9	9
107	Abstract A66: Tumor-associated neutrophils in early stage human lung cancer are not immunosuppressive, but exhibit an inflammatory phenotype and provide accessory signals for T cell activation. , 2015, , .		0
108	Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. <i>Journal of Clinical Investigation</i> , 2014, 124, 5466-5480.	3.9	483

#	ARTICLE	IF	CITATIONS
109	Mesothelin expression is associated with poor outcomes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 675-684.	1.1	42
110	Local hyperthermia treatment of tumors induces CD8+ T cell-mediated resistance against distal and secondary tumors. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 1273-1285.	1.7	156
111	Fibroblast activation protein, a potential diagnostic and therapeutic target for cancerâ€”reply. <i>Human Pathology</i> , 2014, 45, 1553-1554.	1.1	4
112	Transforming Growth Factor β -Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression. <i>Immunity</i> , 2014, 41, 427-439.	6.6	100
113	Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer. <i>Journal of Visualized Experiments</i> , 2014, , .	0.2	20
114	Reprogramming immune responses via microRNA modulation. <i>MicroRNA Diagnostics and Therapeutics</i> , 2014, 1, .	0.0	5
115	Mesothelin expression as a predictive biomarker of breast cancer outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11119-11119.	0.8	0
116	Avirulent <i>Toxoplasma gondii</i> Generates Therapeutic Antitumor Immunity by Reversing Immunosuppression in the Ovarian Cancer Microenvironment. <i>Cancer Research</i> , 2013, 73, 3842-3851.	0.4	86
117	A role for the chemokine receptor CCR6 in mammalian sperm motility and chemotaxis. <i>Journal of Cellular Physiology</i> , 2013, 229, n/a-n/a.	2.0	49
118	Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. <i>Human Pathology</i> , 2013, 44, 2549-2557.	1.1	75
119	Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. <i>Cell Cycle</i> , 2013, 12, 2113-2119.	1.3	74
120	Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. <i>Integrative Biology (United Kingdom)</i> , 2013, 5, 159-171.	0.6	42
121	Pathological Mobilization and Activities of Dendritic Cells in Tumor-Bearing Hosts: Challenges and Opportunities for Immunotherapy of Cancer. <i>Frontiers in Immunology</i> , 2013, 4, 435.	2.2	23
122	Editorial: A clear vision needs some balance. <i>Journal of Leukocyte Biology</i> , 2012, 92, 918-920.	1.5	0
123	Does the β 508-CFTR mutation induce a proinflammatory response in human airway epithelial cells?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2012, 303, L509-L518.	1.3	28
124	Good things come in small packages. <i>Oncolmmunology</i> , 2012, 1, 968-970.	2.1	11
125	Reprogramming Tumor-Associated Dendritic Cells <i>In Vivo</i> Using miRNA Mimetics Triggers Protective Immunity against Ovarian Cancer. <i>Cancer Research</i> , 2012, 72, 1683-1693.	0.4	137
126	Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy. <i>Expert Review of Obstetrics and Gynecology</i> , 2012, 7, 413-419.	0.4	16

#	ARTICLE	IF	CITATIONS
127	Mast cells impair the development of protective anti-tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2273-2282.	2.0	39
128	Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. <i>Journal of Experimental Medicine</i> , 2012, 209, 495-506.	4.2	273
129	Formation of telomeric repeat-containing RNA (TERRA) foci in highly proliferating mouse cerebellar neuronal progenitors and medulloblastoma. <i>Journal of Cell Science</i> , 2012, 125, 4383-94.	1.2	58
130	Anti-tumor immunity: Myeloid leukocytes control the immune landscape. <i>Cellular Immunology</i> , 2012, 278, 21-26.	1.4	19
131	Targeting the Tumor Stroma as a Novel Treatment Strategy for Breast Cancer. <i>Advances in Pharmacology</i> , 2012, 65, 45-61.	1.2	53
132	Mesothelin, a novel immunotherapy target for triple negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 799-804.	1.1	123
133	Double Agents in the War on Cancer: Leukocytes Govern Ovarian Cancer Progression. <i>Oncotarget</i> , 2012, 3, 226-227.	0.8	2
134	It never rains but it pours. <i>Cell Cycle</i> , 2011, 10, 368-369.	1.3	5
135	Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 4246-4255.	3.2	102
136	Harnessing the Effect of Adoptively Transferred Tumor-Reactive T Cells on Endogenous (Host-Derived) Antitumor Immunity. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-11.	3.3	5
137	CD4+ T Cells Elicit Host Immune Responses to MHC Class II ⁺ Ovarian Cancer through CCL5 Secretion and CD40-Mediated Licensing of Dendritic Cells. <i>Journal of Immunology</i> , 2010, 184, 5654-5662.	0.4	75
138	<i>Mycobacterium tuberculosis</i> infection induces <i>il12rb1</i> splicing to generate a novel IL-12R ²¹ isoform that enhances DC migration. <i>Journal of Experimental Medicine</i> , 2010, 207, 591-605.	4.2	44
139	<i>Mycobacterium tuberculosis</i> infection induces <i>il12rb1</i> splicing to generate a novel IL-12R ²¹ isoform that enhances DC migration. <i>Journal of Experimental Medicine</i> , 2010, 207, 897-897.	4.2	0
140	Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. <i>Cell Cycle</i> , 2010, 9, 260-268.	1.3	41
141	CD277 is a Negative Co-stimulatory Molecule Universally Expressed by Ovarian Cancer Microenvironmental Cells. <i>Oncotarget</i> , 2010, 1, 329-338.	0.8	62
142	Abstract LB-360: Fluorescence-based co-registration with protein markers reveals distinct cellular compartments for altered microRNA expression in solid tumors. , 2010, , .		0
143	ORIGINAL ARTICLE: Human Uterine NK Cells Interact with Uterine Macrophages via NKG2D upon Stimulation with PAMPs. <i>American Journal of Reproductive Immunology</i> , 2009, 61, 52-61.	1.2	26
144	<i>In situ</i> Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Inflicting Dendritic Cells from Immunosuppressive to Immunostimulatory Cells. <i>Cancer Research</i> , 2009, 69, 7329-7337.	0.4	124

#	ARTICLE	IF	CITATIONS
145	CCL5-Mediated Endogenous Antitumor Immunity Elicited by Adoptively Transferred Lymphocytes and Dendritic Cell Depletion. <i>Cancer Research</i> , 2009, 69, 6331-6338.	0.4	56
146	Nanomolecular targeting of dendritic cells for ovarian cancer therapy. <i>Future Oncology</i> , 2009, 5, 1189-1192.	1.1	19
147	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. <i>Journal of Translational Medicine</i> , 2009, 7, 49.	1.8	56
148	Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. <i>Journal of Clinical Investigation</i> , 2009, 119, 2231-44.	3.9	177
149	Inflammatory and immune responses induced by nanomaterials: challenges and opportunities for future nanotherapies. <i>Nanotechnology Perceptions</i> , 2009, 5, 195-203.	0.1	1
150	Estradiol regulates MICA expression in human endometrial cells. <i>Clinical Immunology</i> , 2008, 129, 325-332.	1.4	19
151	Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity. <i>Cancer Research</i> , 2008, 68, 7684-7691.	0.4	105
152	PILAR is a novel modulator of human T-cell expansion. <i>Blood</i> , 2008, 112, 1259-1268.	0.6	37
153	Role of Vascular Leukocytes in Ovarian Cancer Neovascularization. , 2008, 622, 273-280.		11
154	Estradiol induces NKG2D ligand expression in human endometrial epithelium. <i>FASEB Journal</i> , 2008, 22, 853.10.	0.2	1
155	Scavenger Receptor-Targeted Leukocyte Depletion Inhibits Peritoneal Ovarian Tumor Progression. <i>Cancer Research</i> , 2007, 67, 4783-4789.	0.4	85
156	Chimeric NKG2D Receptor-Bearing T Cells as Immunotherapy for Ovarian Cancer. <i>Cancer Research</i> , 2007, 67, 5003-5008.	0.4	96
157	Vascular Leukocytes: a Population with Angiogenic and Immunossuppressive Properties Highly Represented in Ovarian Cancer. , 2007, 590, 185-193.		20
158	Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. <i>Cancer Gene Therapy</i> , 2006, 13, 182-193.	2.2	24
159	Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. <i>Cancer Biology and Therapy</i> , 2006, 5, 635-642.	1.5	60
160	Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. <i>Cancer Biology and Therapy</i> , 2006, 5, 867-874.	1.5	20
161	Vascular leukocytes contribute to tumor vascularization. <i>Blood</i> , 2005, 105, 679-681.	0.6	183
162	The role of dendritic cell precursors in tumour vasculogenesis. <i>British Journal of Cancer</i> , 2005, 92, 1182-1187.	2.9	108

#	ARTICLE	IF	CITATIONS
163	Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma. <i>Human Gene Therapy</i> , 2005, 16, 765-778.	1.4	81
164	HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. <i>Molecular Therapy</i> , 2005, 12, 789-802.	3.7	119
165	Immunotherapy for gynaecological malignancies. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1193-1210.	1.4	31
166	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. <i>Nature Medicine</i> , 2004, 10, 942-949.	15.2	4,442
167	Tumor-infiltrating dendritic cell precursors recruited by a β -defensin contribute to vasculogenesis under the influence of Vegf-A. <i>Nature Medicine</i> , 2004, 10, 950-958.	15.2	431
168	Ovarian Carcinoma Expresses the NKG2D Ligand Letal and Promotes the Survival and Expansion of CD28 ⁺ Antitumor T Cells. <i>Cancer Research</i> , 2004, 64, 2175-2182.	0.4	64
169	Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma. <i>Journal of Immunotherapy</i> , 2004, 27, S7.	1.2	0
170	Antioxidant nutrients protect against cyclosporine A nephrotoxicity. <i>Toxicology</i> , 2003, 189, 99-111.	2.0	108
171	Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. <i>New England Journal of Medicine</i> , 2003, 348, 203-213.	13.9	2,930
172	Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver. <i>Protein Science</i> , 2003, 12, 143-152.	3.1	161
173	Distribution of new human β -defensin genes clustered on chromosome 20 in functionally different segments of epididymis. <i>Genomics</i> , 2003, 81, 175-183.	1.3	104
174	LETAL, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells. <i>Cancer Biology and Therapy</i> , 2003, 2, 446-451.	1.5	55
175	T Cells in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2003, 348, 1814-1814.	13.9	1
176	Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma. <i>American Journal of Pathology</i> , 2002, 161, 2295-2309.	1.9	129
177	Different Effects of Glucose Starvation on Expression and Stability of VEGF mRNA Isoforms in Murine Ovarian Cancer Cells. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 860-868.	1.0	65
178	NK-1 receptor gene expression is related to pain in chronic pancreatitis. <i>Pain</i> , 2001, 91, 209-217.	2.0	88
179	Real-Time Quantitative PCR of Telomerase mRNA Is Useful for the Differentiation of Benign and Malignant Pancreatic Disorders. <i>Pancreas</i> , 2001, 22, 331-340.	0.5	25
180	Identification of a novel, multifunctional β -defensin (human β -defensin 3) with specific antimicrobial activity. <i>Cell and Tissue Research</i> , 2001, 306, 257-264.	1.5	371

#	ARTICLE	IF	CITATIONS
181	Structure determination of human and murine beta-defensins reveals structural conservation in the absence of significant sequence similarity. <i>Protein Science</i> , 2001, 10, 2470-2479.	3.1	115
182	Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. <i>International Journal of Cancer</i> , 2000, 88, 12-20.	2.3	130
183	Macrophages infiltrating the tissue in chronic pancreatitis express the chemokine receptor CCR5. <i>Surgery</i> , 2000, 128, 806-814.	1.0	64
184	Interference of Chylomicrons in Analysis of Platelets by Flow Cytometry. <i>Thrombosis Research</i> , 1998, 91, 49-52.	0.8	13
185	Increased Hydrogen Peroxide Formation in Polymorphonuclear Leukocytes of IDDM Patients. <i>Diabetes Care</i> , 1998, 21, 326-327.	4.3	14
186	CYCLOSPORINE INCREASES LOCAL GLOMERULAR SYNTHESIS OF REACTIVE OXYGEN SPECIES IN RATS1. <i>Transplantation</i> , 1998, 66, 1325-1329.	0.5	55
187	Interference from lipemia in cell count by hematology analyzers. <i>Clinical Chemistry</i> , 1996, 42, 987-988.	1.5	22
188	Evaluation of zone electrophoresis of serum proteins performed on the Helena Laboratories rapid electrophoresis analyser. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1995, 55, 729-731.	0.6	2
189	SATB1 Expression Governs Follicular Helper T-cell-Triggered Tertiary Lymphoid Structure Assembly. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0